Combinatorial strategies to target RAS-driven cancers.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS proteins are key regulators of cell signaling, and their dysregulation drives many cancers.
• RAS was historically considered undruggable, but recent advances have led to the development of targeted inhibitors.
• Mutant-specific KRAS inhibitors have shown clinical success, but responses are often incomplete.

Purpose of the Study:

• To review and discuss combinatorial strategies for treating RAS-driven cancers.
• To explore mechanistic concepts for targeting RAS and other vulnerabilities.
• To highlight the importance of patient-specific factors in treatment response.

Main Methods:

• Review of current literature on RAS pathway inhibitors and combinatorial approaches.
• Analysis of mechanistic concepts for vertical and alternative combination strategies.
• Discussion of genetic, epigenetic, and tumor-specific variables influencing treatment efficacy.

Main Results:

• Directly targeting RAS, particularly KRAS, has clinical validation.
• Combinatorial approaches, including vertical and co-targeting strategies, are being investigated.
• Treatment efficacy is influenced by complex biological and tumor-specific factors.

Conclusions:

• More effective treatments for RAS-driven cancers likely require combinatorial strategies.
• Co-targeting RAS with other vulnerabilities may offer an alternative to profound pathway suppression.
• Clinical success depends on achieving a therapeutic window and prospectively selecting responsive patients.